Objective: To review studies investigating the following: whether exposing developing infants to antipsychotic medication during pregnancy and lactation is associated with increased risks of teratogenic, neonatal, and long-term neurobehavioural sequelae; whether schizophrenia itself affects pregnancy outcome; and whether the course of schizophrenia symptoms is altered by pregnancy and lactation.
T here is a need to evaluate the safety of antipsychotic medications during pregnancy and lactation. Women with schizophrenia have sexual practices similar to those of demographically matched control subjects with respect to frequency of sex and the age at which they become sexually active. They are, however, more likely to have unplanned pregnancies (1) . Unplanned pregnancies among women with schizophrenia and among women taking antipsychotics during their reproductive years expose developing infants to these medications. Given this situation, physicians need information to advise women with schizophrenia about the relative risks of exposing developing infants to antipsychotic medications and to help them to weigh those risks against the potential risks they and their infant may incur if their psychotic illness is not treated. It is important to limit treatment of mothers and exposed infants to situations in which the risk from the untreated psychotic illness is presumed to exceed the risk associated with drug treatment.
Methods
We conducted a computerized Medline search for the period between January 1, 1966, and December 1, 2001 . We used the following key words: pregnancy, postpartum, lactation, breast-feeding, child development, infant development, schizophrenia, psychosis, antipsychotic, clozapine, olanzapine, risperidone, and quetiapine. The resultant articles were cross-referenced for other relevant articles not identified in the initial search.
Pregnancy Outcome for Women With Schizophrenia
In 1960, Sobel found that women diagnosed with a psychotic illness were twice as likely as women in the general population to have a pregnancy resulting in congenital malformation or death, irrespective of chlorpromazine exposure during pregnancy (2) . Other researchers reported a higher rate of perinatal death in the offspring of mothers with schizophrenia-a rate not statistically associated with exposure to typical antipsychotic medication (3) . Subsequent literature reviews concluded that births to parents with schizophrenia did not carry increased risk for poor obstetrical outcomes (4, 5) . However, when metaanalysis was used to systematically examine the data reviewed in these studies, there was evidence of a small but significantly increased risk for low birth weight and poor neonatal condition in infants born to patients with schizophrenia (6) . A Danish 20-year retrospective review found increased risk of preterm delivery, low birth weight, and small size for gestational age in newborn children of women with schizophrenia (7). These parameters for poor obstetrical outcome were chosen because they can be clearly defined and are strongly correlated with increased infant morbidity, mortality, and neurodevelopmental impairment (8) .
Previously, Bennedsen had reviewed the literature and found that women with schizophrenia have higher prevalence rates of cigarette smoking, alcohol use, drug use, and low socioeconomic status (9)-all of which are strongly associated in the general population with low birth weight, preterm birth, and perinatal death. This recent literature clarifies that women with schizophrenia are at increased risk for poor obstetrical outcomes and that many factors may contribute to this.
It is in this context that one must evaluate studies looking at the extent to which, if any, antipsychotic medication exposure during infant development contributes to poor obstetrical outcomes in the population with schizophrenia. No antipsychotic medication has been approved for use during pregnancy and lactation, and the risks of infant exposure must be weighed against the risks of untreated maternal illness. The potential risks to the infant of medication exposure at this time include congenital abnormalities, neonatal toxicity, and long-term neurobehavioural sequelae. (Table 1) Few studies directly assess the long-term impact on child development of exposure to typical antipsychotic medication during pregnancy. A prospective study of 52 children exposed to 50 to 150 mg of chlorpromazine during pregnancy and postpartum reported no difference from their siblings or peers in birth, developmental history, tests of intelligence, observed behaviour, or mental disturbance (10) . Unfortunately, only data from 2 of the 52 cases are presented in the paper, and methods for assessing the outcome measures are not reported. In 1990, Stika and others identified 68 infants exposed to 5 to 25 mg of chlorpromazine during pregnancy (11) . At age 10 years, these children were compared with nonexposed control subjects, and no behavioural differences were detected. Both of these studies are methodologically flawed and therefore difficult to interpret clinically.
Typical Antipsychotic Medication Exposure During Pregnancy
In contrast, Platt and others found that prenatal exposure to typical antipsychotic medication significantly affected the height and weight of children followed prospectively from pregnancy to age 7 years (12) . Children born to parents with a psychiatric diagnosis and exposed to more than 2 months of typical antipsychotic medication during pregnancy were 3 cm taller at age 7 years than were nonexposed children of parents with a psychiatric diagnosis. This statistically significant increase in height was found regardless of whether these children were bottle-or breast-fed postpartum. Children born to psychiatrically well parents and exposed to typical antipsychotics during the treatment of maternal hyperemesis showed a statistically significant increase in height at 4 months and in weight at 1 year. However, the significance of these effects disappeared by age 7 years. That similar trends were seen in this group, likely exposed to a lesser dosage and shorter duration of medication, supports the argument that the differences observed are due to medication effects and are not simply artifacts of parental psychiatric diagnosis.
Exposure to Typical Antipsychotic Medication During Lactation
There are case reports of infant exposure to flupenthixol, zuclopenthixol (13), perphenazine (14) , haloperidol (15, 16) , and chlorpromazine (17,18) during breast-feeding. Levels of these typical antipsychotics in breast milk were less than 1% of the maternal daily dosage. The exposed infants were followed from 2 weeks to 1 year, and none were reported to display any abnormalities; however, there was no indication as to how the infants were assessed.
Yoshida and others conducted an open prospective controlled trial comparing the development of 2 groups of infants (19) . Twelve infants were exposed postpartum through their mothers' breast milk to haloperidol, chlorpromazine, trifluperazine, or a combination of these medications. Eighteen infants were bottle-fed by mothers taking similar medications for similar diagnoses. The mean duration of breast-feeding was 17 weeks, and on average, infants were exposed to less than 3% of the maternal daily dosage per kg of body weight. All infants were normal on the Amiel-Tison neurological examination. The infants were also assessed using the Bayley Scale of Infant Development (20) .
Three of the breast-fed infants showed a significant decrease in their psychomotor index at age 12 to 18 months. Two of these infants also showed a significant decrease in their mental index at that time. The mothers of these infants were diagnosed with bipolar depression and mania; they were the only mothers simultaneously prescribed 2 antipsychotics: haloperidol (20 to 40 mg) and chlorpromazine (400 to 600 mg). The authors acknowledge that confounding factors in this study made the developmental outcome of these infants difficult to link directly to medication effects. These factors included severe maternal illness that required separation of infant and mother and lack of follow-up with the bottle-fed group after 11 months. Further, interpretation of Bayley scores obtained under age 12 months must be made with caution, because these scores have not been shown to significantly predict future cognitive and motor performance (21) . Nevertheless, given the lack of information in this area, it may be wise to follow Yoshida and others' advice and proceed with caution when considering breast-feeding for women taking typical antipsychotics in the upper end of their recommended ranges.
Atypical Antipsychotic Medication Exposure During Pregnancy (Table 2)
Olanzapine Twenty-three prospectively identified pregnancies in which infants were exposed to olanzapine dosages ranging from 5 to 25 mg daily (22) showed rates of spontaneous abortion, stillbirth, and prematurity similar to the general population rates (23, 24) .
Two women with no family or personal history of diabetes developed gestational diabetes (22) . Another woman, with a family history of diabetes, was reported to have developed gestational diabetes, hypertension, and preeclampsia while taking 15 to 20 mg of olanzapine daily throughout pregnancy. The baby was reported "viable at birth" (25) . Because these events have not been studied prospectively, one cannot conclude that they are due to the antipsychotic medication exposure; however, some of these events are similar to side effects reported by adults prescribed these medications.
b
See text for human studies.
Clozapine
In a 1997 paper, Stoner and others comment on the possible association between seizure and clozapine exposure, although the infant described was also exposed to typical antipsychotics, lithium, and benzodiazepines (62). Baker and Chengappa speculate that the gastroesophageal reflux in this infant may also be linked to clozapine exposure (26) .
Of the 2 reported cases of gestational diabetes, one woman had a history of diabetes prior to pregnancy or treatment with clozapine.
Atypical Antipsychotic Medication Exposure During Lactation

Olanzapine
We reviewed 3 case reports of breast-fed infants whose mothers were taking olanzapine (22, 27) . However, it is premature to interpret the infant outcomes from these case reports. In all 3, breast-milk levels of the drug were not reported. In 1 infant, exposed to clozapine 10 mg/d, the drug serum levels were taken and were undetectable. This infant could not roll from back to front at age 7 months but had a "normal" developmental exam by age 11 months (27) . A second infant exposed at birth developed jaundice, sedation, heart murmur, and cardiomegally. Jaundice and sedation continued despite the mother being switched to a typical antipsychotic (22) . The third infant was reported to have no adverse symptoms (22) .
Clozapine, Risperidone, and Quetiapine
The literature has no case reports of infant exposure to clozapine, risperidone, or quetiapine during breast-feeding. There are 2 case reports on transmission of clozapine and risperidone into breast milk of women taking these medications and bottle-feeding their infants. Barnas and others measured levels of clozapine in the breast milk of a mother prescribed 50 to 100 mg of clozapine daily and found that levels of clozapine in the foremilk were 2.8 to 4.3 times the levels of clozapine in the maternal plasma (28). Hill and others calculated risperidone and the active metabolite 9-hydroxyrisperidone to have respective milk-to-plasma ratios of 0.42 and 0.24 in 24 hours, with an estimated exposure of 4.3% of weight-adjusted maternal daily dosage (29) .
Course of Schizophrenia During Pregnancy and Postpartum
The literature has limited and contradictory information on the course of schizophrenia in pregnancy and postpartum. In 1984, McNeil and others observed that patients with schizophrenia were more likely to report their mental health to be "a little worse" or "much worse" during pregnancy, compared with healthy control subjects (30) . However, chart reviews showed that patients who reported worsening of mental health were just as likely to be described as "improved" or "unchanged" by their clinician. Despite the discrepancy, the authors concluded that during pregnancy women were much more likely to experience a worsening of psychosis than an improvement. In 1989, Krener and others reported on 14 Olanzapine n = 23: no increase in major malformations vs general population (22) . n = 1: healthy baby born to a mother treated from 18 weeks gestation with olanzapine 10 mg daily (27) . women who had a DSM-III-R diagnosis of psychosis either during pregnancy or within the 2 years preceding pregnancy (31) . Only 48% of these women were initially treated with antipsychotic medications, and all of them were able to decrease the dosage or discontinue their medication during pregnancy. The authors suggested that this reflected a relative amelioration of psychotic symptoms during pregnancy, because less antipsychotic medication was prescribed.
In 1987, McNeil reported that women with schizophrenia had the lowest risk for psychosis in the first 6 months postpartum, compared with women diagnosed with other functional psychoses (32) The contradictory results of the above studies likely reflect not only the subject's complexity but also the methodological difficulties present in all these studies-difficulties that limit our ability to draw conclusions from their results. These studies are limited by poorly defined diagnostic criteria, poorly defined symptom measures, and lack of information regarding medication dosage or duration.
Terp and Mortensen undertook a 20-year retrospective review of the course of postpartum psychosis, comparing the Danish psychiatric registry with the central birth registry (33) . They looked at several ICD-8 diagnoses with psychotic symptomatology, including schizophrenia. For schizophrenia, they found that the relative risk of first admission is not increased during the postpartum period, readmission is reduced in the postpartum period, and admission is not increased before delivery. They acknowledge that these results are difficult to interpret because, while they may reflect ameliorated symptoms, they may only reflect the decreased fertility rates (30% to 80% of the general population rate) recorded in patients with schizophrenia between the years 1893 and 1979 (34) .
Discussion
The literature is clear that women with schizophrenia are at higher risk for the obstetrical complications of preterm delivery, infants with low birth weight, and babies that are small for their gestational age. We do not currently understand what may be most important in contributing to, or predicting, a poor obstetrical outcome for these women. We suggest that treating physicians take a harm-reduction approach during pregnancy and lactation and actively encourage their patients to decrease or stop cigarette smoking, alcohol use, and drug use. We recommend assessing the stability and availability of secondary caregivers for mother and infant. Community resources that will enhance the mother's psychiatric stability, functioning in the community, and ability to parent should be identified and put in place to ensure optimal prenatal and perinatal care.
Current information about the impact of pregnancy on the course of schizophrenia is limited and difficult to interpret; thus, treatment guidelines during this time in a woman's life are undefined. Until more research is done, it is important that treatment recommendations reflect our current understanding of the illness course in the population with schizophrenia. Reviews by Gilbert (35) and Baldessarini (36) report that patients with schizophrenia are at greatest risk of relapse within the first 3 months after antipsychotic withdrawal and reach maximal risk within 12 months. The rate of antipsychotic withdrawal is also important: tapering medication over fewer than 2 weeks results in relapse rates that are 5 to 6 times higher than those encountered when medications are tapered over 2 months or more. These data suggest that stopping medications, especially abruptly, during pregnancy or postpartum potentially places the mother at high risk for relapse. The potential consequences of a psychotic relapse may be severe and include maternal suicide and infanticide.
These potentially serious ramifications of discontinuing medication, as well as the known potential risk of medication exposure during infant development, need to be discussed carefully with the mother. Treatment with medications should be limited to situations in which the potential risk of exposing the developing infant to medications is outweighed by the risk posed by untreated maternal illness. Thus, decisions regarding medication recommendations during pregnancy and lactation should include an evaluation of a woman's specific symptoms, illness course, and illness severity. Physicians should clearly communicate recommendations for psychiatric management to other professionals involved in their patients' medical care and should attempt to engage and educate members of each patient's support system, where possible.
If possible, phenothiazines should be avoided during the first trimester, because they are associated with a statistically significant increase in congenital anomalies.
Atypical antipsychotic medications may pose unique risks to women during their reproductive years. While women taking typical antipsychotics have shown suppressed fertility rates, it appears that, when taking atypical antipsychotics, their fertility rates may approach those of the general population (37) . It is therefore important that patients have access to counselling about available methods of birth control. Recent studies have found that patients treated with clozapine and olanzapine have an increased risk for significant weight gain and for developing Type 2 diabetes mellitus (38) (39) (40) . Both of these medical complications carry increased risk of poor obstetrical outcomes for both mother and infant (41) . Maternal diabetes during pregnancy places the developing infant at greater risk for perinatal mortality, prematurity, congenital abnormalities (neural tube defects), macrosomia (which can lead to shoulder dystocia and Caesarean section), and developing diabetes in the future.
Otherwise, because no group of medications has been identified as clearly presenting a decreased risk to developing infants, we suggest a harm-reduction approach that is best achieved by maintaining the mother on the lowest dosage possible of the medication that has proved best able to manage her psychiatric symptoms.
Owing to scant data in the literature, we are unable to recommend breast-feeding while taking any antipsychotic medication. Where mothers insist on breast-feeding, it would appear especially prudent to avoid clozapine or combinations of typical antipsychotics with dosages in the upper end of their recommended ranges, if at all possible.
It is clear that we urgently need more research in this very complex area if we are to provide more detailed information to women with schizophrenia who are pregnant or who are trying to conceive. Research using standardized diagnostic and assessment scales that attempt to track the course of schizophrenia during pregnancy and postpartum may help clarify recommendations regarding medications during this period. We also need more specific information about the safety of individual medications during pregnancy and lactation. This will require prospective studies that measure levels of medication in the mother's plasma and breast milk and in the infant's serum and urine. Neonatal assessment of infants exposed to medications during pregnancy and lactation will be important, as will following these children over the long term. We need to determine whether developmental difficulties can be found consistently in the group of children exposed to medication during their development but not in children with similar environmental and genetic risks who were not exposed to medications. Finally, the increased risk of diabetes and obesity that appears to accompany the use of atypical antipsychotic medication may require new guidelines for screening and treating these physical complications in pregnant women taking these medications.
Antipsychotic Medication During Pregnancy and Lactation in Women With Schizophrenia: Evaluating the Risk
Résumé : Les antipsychotiques durant la grossesse et la lactation chez les femmes schizophrènes : évaluation du risque Objectif : Passer en revue les études qui s'interrogent sur les sujets suivants : si exposer des bébés en développement aux antipsychotiques durant la grossesse et la lactation est associé à des risques accrus de séquelles tératogéniques, néonatales et neurocomportementales à long terme; si la schizophrénie en elle-même affecte l'issue de la grossesse; et si l'évolution des symptômes de la schizophrénie est modifiée par la grossesse et la lactation.
Méthode : Nous résumons les résultats d'articles repérés par une recherche dans MedLine pour la pé-riode du 1 er janvier 1966 au 1 er décembre 2001.
Résultats : Les femmes souffrant de schizophrénie sont à risque accru de mauvais résultats obstétri-ques, y compris l'accouchement prématuré, le faible poids à la naissance, et des foetus qui sont petits pour leur âge gestationnel. Un manque d'information dans la documentation complique la tâche de commenter le risque relatif d'exposer des bébés en développement aux antipsychotiques atypiques. Toutefois, les antipsychotiques typiques semblent comporter un risque accru de malformations congé-nitales quand le foetus est exposé aux phénothiazines entre la 4 e et la 10 e semaine de gestation. Le manque d'information empêche aussi de comprendre si les changements associés à la grossesse et à la lactation modifient significativement l'évolution des symptômes de la schizophrénie.
Conclusion :
Il faut plus d'études pour que les médecins puissent informer plus précisément les femmes sur les risques relatifs de l'utilisation d'antipsychotiques durant la grossesse et la lactation. Les connaissances accrues sur les risques de l'exposition aux médicaments permettront aux cliniciens de limiter le traitement aux situations où le risque de la maladie maternelle non traitée est plus grand que le risque d'exposer un bébé en développement aux médicaments.
